Specimen letter to physical shareholders on dividend withheld for FY 2025-26 pending KYC
The company shared a specimen of the letter sent to shareholders whose FY 2025-26 final dividend has been withheld because KYC details for physical folios are incomplete.
- Record date
- July 24, 2026
- Dividend withheld reason
- KYC details for physical folios incomplete
- Required forms
- Forms ISR-1, ISR-2 and SH-13/ISR-3
- RTA
- Alankit Assignments Limited
- Payment mode
- Electronic only per SEBI norms
What was shared
The company placed on record the specimen of an intimation letter sent to security holders whose final dividend for the financial year 2025-26 has been withheld because KYC documents were not submitted.
Why the dividend is withheld
- Dividend payment through any mode other than electronic mode has been discontinued under SEBI norms.
- Shareholders holding shares in physical form must have PAN, postal address, email, mobile number, bank account details and specimen signature registered in their folio.
- Where these details are incomplete or not updated in the records of the company or the RTA, the final dividend has been withheld.
What the letter contains
The letter gives each holder their shares held on the record date of July 24, 2026, dividend per share, gross dividend, tax deducted at source, net dividend, rate of tax, payment date, status of payment and reason for withholding.
What affected holders must do
- Form ISR-1 for KYC update with self-attested supporting documents.
- Form ISR-2 for banker attestation of signature with original cancelled cheque or self-attested bank passbook or statement.
- Form SH-13 for nomination, or Form ISR-3 to opt out of nomination.
- Send self-attested hard copies to the RTA, Alankit Assignments Limited, New Delhi.
What it means
This is an administrative and investor-servicing communication. The withheld amount is not forfeited; it is remitted electronically once the KYC and bank details are registered and successfully validated, subject to applicable tax requirements. It affects only holders with physical shareholdings whose records are incomplete, not the company's operations.
Also from Jubilant Pharmova
Board meeting on October 12, 2026 to consider fund raising via NCDs and shareholder approval
7 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.